Applying our expertise in early-stage science and clinical development to invest in best-in-class life sciences opportunities.
Adding value through scientific expertise, clinical insights, and capital
The Translational Sciences group at UPMC Enterprises combines scientific, clinical, and investment expertise to invest $1B by 2024 in life science companies of all stages that are targeting diseases of high unmet medical need. We accelerate the translation of scientific discoveries from bench to bedside, form companies, and invest externally in companies across geographies that are developing innovative therapies and products. In additional to capital, we provide full access to UPMCs vast clinical, payer, and operational resources and expertise.
Committed to disease areas with high unmet need and approaches based on emerging science
Portfolio Snapshot: Building Avista
Translational Sciences Team
Our people have the experience and connections to find and support the ideas that will enable life changing medicine.